4.12
Geneesmiddel-Receptor Interactie: Agonist
Agonisten zijn geneesmiddelen die interageren met specifieke receptoren in het lichaam om een biologische respons te produceren. Wanneer een agonist…
An agonist is a drug that binds and activates the receptor to elicit a cellular response similar to the endogenous ligand.
In a drug-receptor interaction model, a receptor exists in an equilibrium of two conformations: inactive or Ri and active or Ra. The Ri form produces no effect even when bound to a drug, while Ra shows constitutive activity; that is, it can produce a small effect even without drugs.
A drug's relative affinity for the Ri or Ra forms determines its efficacy in causing an effect. In the order of decreasing efficacy, agonists can be full, partial, or inverse.
Full agonists have a strong affinity for the Ra form and produce a maximal response by occupying fewer available receptors.
Partial agonists have an intermediate affinity for Ra and Ri forms. Even with full occupancy of all receptors, they only produce a submaximal response.
Lastly, inverse agonists have a stronger affinity for the Ri conformation and stabilize the resting state of the receptors. So, their effect is opposite to that of an agonist.
Q1: What is an agonist and how does it activate receptors?
An agonist is a drug that binds to and activates receptors to produce a cellular response similar to the endogenous ligand. Agonists work by binding directly to the receptor's active site or to allosteric sites, mimicking the endogenous ligand's action and triggering signal transduction within the cell. This activation leads to physiological effects essential for therapeutic action in medical treatments.
Q2: How do receptor conformations affect agonist efficacy?
Receptors exist in two conformations: inactive (Ri) and active (Ra). A drug's relative affinity for these forms determines its efficacy. The Ri form produces no effect when bound, while Ra shows constitutive activity and can produce effects without drugs. An agonist's ability to preferentially bind the Ra conformation directly influences its capacity to elicit a cellular response.
Q3: What is the difference between full and partial agonists?
Full agonists have strong affinity for the active receptor conformation (Ra) and produce maximal response by occupying fewer available receptors. Partial agonists have intermediate affinity for both Ra and Ri forms, producing only submaximal response even with full receptor occupancy. This difference in dose response relationship potency and efficacy determines their clinical effectiveness and therapeutic applications.
Q4: How do inverse agonists differ from full agonists?
Inverse agonists have stronger affinity for the inactive receptor conformation (Ri) and stabilize the resting state of receptors, producing effects opposite to agonists. Unlike full agonists that activate receptors, inverse agonists suppress constitutive activity and reduce baseline receptor signaling. This mechanism makes them useful for treating conditions involving excessive receptor activity.
Q5: What are clinical examples of full agonists and partial agonists?
Phenylephrine is a full agonist for α1-adrenoceptors that activates nasal receptors, causing vasoconstriction to reduce edema and congestion. Partial agonists like buprenorphine and varenicline are used clinically for addiction treatment. These drugs activate opioid and nicotinic receptors sufficiently to prevent cravings for heroin and nicotine while minimizing abuse potential.
Q6: How does pimavanserin work as an inverse agonist?
Pimavanserin is an inverse agonist of the 5-HT2A receptor that treats hallucinations associated with Parkinson's disease. By preferentially binding the inactive receptor conformation, it suppresses the constitutive activity of these receptors. This mechanism reduces abnormal serotonin signaling responsible for hallucinations without blocking normal receptor function.
Q7: Why is understanding agonist-receptor binding important for drug development?
Understanding how agonists interact with receptors based on their affinity for inactive and active conformations is crucial for drug development and personalized medicine. This knowledge helps researchers design drugs with desired efficacy profiles, predict therapeutic outcomes, and minimize adverse effects. Studying these interactions unravels mechanisms underlying drug action and improves therapeutic strategies.